Wonil Kim

Company: Aston Science Inc

Job title: Chief Scientific Officer

Bio:

Wonil Kim, Ph.D., is the Chief Scientific Officer at Aston Sci., where he leads the strategic development of innovative mRNA-based therapeutic and prophylactic vaccines, including the AI-driven Th-Vac® platform targeting cancer and infectious diseases. Wonil earned his Ph.D. in Molecular, Cellular, Developmental Biology, and Genetics from the University of Minnesota and has held prominent R&D leadership roles at GeneOne Life Science and Cyrus Therapeutics. His experience also includes serving as a staff scientist at St. Jude Children?s Research Hospital, focusing on drug screening and cancer biology. Dr. Kim?s expertise covers all aspects of mRNA-based drug development, solidifying his status as a key innovator in the field.

Seminars:

Th-Vac® Platform: AI-Based in Silico Epitope Screening for CD4+ T Cell- Mediated mRNA Cancer Vaccine Immunotherapy 3:20 pm

Th-Vac® is an AI-powered system designed to help create mRNA cancer vaccines that activate CD4+ helper T cells Harnessing this technology to develop mRNA vaccines that can specifically target cancer associated antigens such as TROP2, PD-L1, IDO, and KRAS Addressing the current challenges in cancer immunotherapy and enhancing future treatment optionsRead more

day: Conference Day One